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ORIGINAL INVESTIGATION
Impaired coronary microcirculation 
in type 2 diabetic patients is associated 
with elevated circulating regulatory T cells 
and reduced number of IL-21R+ T cells
Bernt Johan von Scholten1*†, Alexander Rosendahl2,3,7†, Philip Hasbak4, Regine Bergholdt2, Andreas Kjaer4, 
Peter Rossing1,5,6 and Tine W. Hansen1
Abstract 
Background: Low-grade systemic inflammation is considered to participate in the progression of type 2 diabetes 
(T2D) and in diabetic complications.
Methods: To determine if circulating leukocytes were abnormally regulated in T2D patients, 8-color flow-cytometry 
(FACS) analysis was performed in a cross-sectional study of 37 T2D patients and 16 controls. Data obtained from the 
FACS analysis were compared to coronary flow reserve (CFR), assessed by Rb82-PET-imaging, to uncover inflammatory 
signatures associated with impaired CFR.
Results: Presence of T2D was associated with T cell attenuation characterized by reduced overall T cell, Th17, IL-
21R+, Treg’s and TLR4+ T cells, while the monocyte population showed enhanced TLR4 expression. Further, our data 
revealed reduced M1-like CD11c expression in T2D which was associated with impaired CFR. In contrast, we show, for 
the first time in T2D, increased TLR4 expression on CD8 T cells, increased Treg cell number and Treg maturation and 
reduced IL-21R expression on CD8 T cells to be functionally associated with impaired CFR.
Conclusions: Our demonstration that HbA1c inversely correlates to several T cell populations suggests that T cells 
may play disease modulating roles in T2D. Further, the novel association between impaired CFR and regulatory T cells 
and IL-21R+ T cells imply an intricate balance in maintaining tissue homeostasis in vascular diabetic complications.
Keywords: Type 2 diabetes, Flow-cytometry (FACS) analysis, Coronary microcirculation, Coronary flow reserve, 
Inflammation, Cardiovascular disease, Peripheral blood, Monocyte sub-populations
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Background
Inflammation is a fundamental biological process not 
only with the role to enable host protection against path-
ogens, but also to stimulate and modulate repair and 
healing when cellular damage occurs. During an inflam-
matory event, once the initial insult is contained, the pri-
mary objective is to restore tissue homeostasis. Failure to 
appropriately resolve an inflammatory stimulus can result 
in persistent immune system activation, which can cause 
tissue damage and disease. Immune cells are the primary 
effectors of most inflammatory reactions [1]. Evidence 
suggests that type 2 diabetes (T2D) can be character-
ized as an inflammatory disease [2]. The vast majority of 
patients with T2D are overweight to obese, and obesity 
has been linked to insulin resistance, hyperglycaemia, 
hyperlipidaemia and elevated inflammatory circulat-
ing factors [3]. Elevated levels of acute-phase proteins 
(e.g. C-reactive protein) as well as several cytokines (e.g. 
IL-6 and TNFα) are present in patients with T2D and are 
shown to be modulated during disease progression [4, 5]. 
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Patients with T2D are at high risk of cardiovascular dis-
ease [6], and inflammatory processes play an important 
role in the development of cardiovascular disease [7]. 
Coronary flow reserve (CFR) is an important physiologi-
cal parameter in the coronary circulation that reflects the 
function of large epicardial arteries and the microcircu-
lation. Impaired CFR has previously been described as a 
powerful, independent correlate to higher cardiac mor-
tality among patients with diabetes [8].
IL-21R positive T cells have been shown to exhibit 
non-redundant roles in several systemic inflammatory 
conditions e.g. rheumatoid arthritis [9, 10]. TLR4 is clas-
sically associated with myeloid cells and with function as 
signalling receptor through which the cells sense bacte-
rial infections [11]. Recently, expression and activation of 
TLR4 on various lymphoid cells, e.g. CD4+ T cells, was 
demonstrated, and has been suggested to act as a nega-
tive regulator of the immune response limiting the exces-
sive inflammation [12, 13].
The present study investigated if altered leukocyte sub-
populations were present in peripheral blood in patients 
with T2D compared to healthy controls. Further, the 
association between leukocyte sub-populations and 
impaired coronary microcirculation (assessed by CFR) 
was determined to identify potential novel biomark-
ers or functional explanations so far not known in T2D 
subjects.
Methods
Study population
From April to December 2013, we conducted a cross-
sectional study at Steno Diabetes Center with the aim to 
assess the value of cardiac positron emission tomogra-
phy/computed tomography (PET/CT) for non-invasive 
estimation of microvascular function and structure [14]. 
A total of 60 consecutive patients with T2D (defined 
according to the WHO criteria) and 30 non-diabetic 
controls were included. Participants were aged between 
35 and 80 years, with the ability to understand and give 
informed consent. Participants were excluded if one of 
the following characteristics were present: (1) history of 
coronary heart disease or other cardiovascular disease 
(including stroke) or symptoms from the heart, assessed 
from patient files and thorough interviews and question-
naires; (2) asthma or chronic obstructive pulmonary 
disease requiring treatment; (3) kidney disease other 
than diabetic nephropathy; (4) end-stage renal disease; 
(5) office blood pressure >200/110 mmHg; (6) second or 
third degree atrioventricular block; or (7) pregnancy or 
lactating.
In this per-protocol specified sub-study, 37 of the 
patients with T2D and 16 of the non-diabetic control 
persons were included. The inclusion of the participants 
was based on time of the day for the drawing of the fresh 
blood sample at Steno Diabetes Center, to allow the flow 
cytometric analyses to be completed on the same day. 
Hence, only participants with a drawing of the blood per-
formed before 12 p.m. were included.
Power calculation was performed for the primary study 
[14] and not for this sub-study. Analyses presented in this 
manuscript were hypothesis generating, and based on 
existing literature we anticipated that our sample size was 
sufficient.
The study was conducted in compliance with the Dec-
laration of Helsinki. All participants gave informed writ-
ten consent and the study protocol was approved by The 
Research Ethics Committee, Capital Region of Denmark.
Clinical measurements
HbA1c was measured by high-performance liquid chro-
matography and plasma creatinine by an enzymatic 
method (Hitachi 912, Roche Diagnostics, Germany).
Current smoking was defined as one or more ciga-
rettes/cigars/pipes a day. Weight and height of each 
participant were measured, and body mass index was cal-
culated as body weight in kilograms divided by height in 
meter squared.
Hybrid cardiac positron emission tomography (PET)/
computed tomography (CT) imaging
A dynamic, gated cardiac PET study was performed 
using a hybrid PET/CT scanner in 3D mode (Siemens 
Biograph™ mCT 128, Siemens, Germany) following 
administration of 1100 MBq 82Rb (Cardiogen∙82®, Bracco 
Diagnostics Inc., USA). Myocardial Blood Flow was cal-
culated automatically with Siemens Syngo MBF 2.3® (Sie-
mens Medical Solutions, USA), using one-compartment 
tracer kinetic models for 82Rb, including regional uptake 
and clearance parameters, blood to myocardium spill-
over and partial volume corrections, and the extraction 
curve from Lortie et  al. [15]. Maximal hyperemia was 
induced with adenosine infused at 140  μg/kg/min for 
6 min. Participants abstained from all caffeine or meth-
ylxanthine containing substances for at least 18 h prior to 
the cardiac PET scan.
Flow cytometry analysis
Flow cytometric analysis was performed according to 
standard procedures and samples acquired on a FACS-
Fortessa equipped with blue, red and violet laser fol-
lowed by data analysis using FACSdiva software (BD 
Biosciences). Briefly, to inhibit unspecific binding cells 
were blocked with anti-CD16 (BD Biosciences) and anti-
CD32 (BD Pharmingen). This was followed by surface 
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staining of 7-amino-actinomycin D (7-AAD) (Biolegend), 
CD45 (Biolegend), CD3 (eBioscience), CD4 (Biolegend), 
CD8 (BD), CD19 (eBioscience) IL-21R (BD Pharmin-
gen), ICOS (eBioscience), CXCR5 (BD), CCR6 (Bioleg-
end), CD14 (BD), CD16 (Biolegend), CD11c (Biolegend), 
CD163 (Biolegend), TLR4 (Biolegend), CD68 (Bioleg-
end), CD25 (Biolegend), CD127 (BD), CTLA-4 (Biosci-
ence), FoxP3 (Biolegend), GITR (Biolegend).
To determine total cell number in the whole blood 
samples, total cell count analysis was performed using 
123 count beads (eBioscience) according to manufactures 
description.
Mean fluorescence intensity (MFI) was determined 
using the geometric mean value after staining with the 
marker antibody. To verify specificity, a control with 
a threefold higher concentration of an isotype control 
antibody was used both in healthy control subjects and 
in the patients. The MFI after isotype control was similar 
between healthy and patient samples and hence the value 
used and shown is the uncorrected MFI value obtained 
after each marker antibody.
Th17 cells were determined by identifying CD3+ 
CD4+ CCR6+ cells that upon first 1  h activation with 
50  ng/ml PMA and 1  mg/ml ionomycin in (RPMI+ 
10 % FCS and P/S, Sigma) and then an additional 5 h in 
the presence of 10  mg/ml BrefeldinA were positive for 
IL-17 (eBio64DEC17, eBioscience) after fixation and 
permeabilization.
Statistical analysis
Based on their graphical distribution and the results of 
the Shapiro-Wilk test [(p < 0.05); indicating a non-normal 
distribution], the skewed variables were log-transformed 
using the natural (ln) logarithm prior to the t test and lin-
ear regression analysis. Differences between patients and 
controls were assessed by independent samples t test for 
continuous and χ2 for categorical variables.
First, we evaluated the unadjusted levels of the cell 
markers in the patients and controls.
Next, analysis of covariance compared levels of the cell 
markers between the patients and controls, and multi-
variate linear regression analysis was used to assess the 
independently association with HbA1c and the different 
cell markers in the total population (n = 53) and CFR in 
the patients (n =  37). We took the following confound-
ers into account: age, sex, body mass index and smoking. 
Due to bias of indication, we did not include variables for 
medical treatment, blood pressure or cholesterol. The 
adjusted analyses of CFR additionally included diabetes 
duration. A 2-tailed p  <  0.05 was considered statistical 
significant. Statistical analyses were performed using SAS 
software (version 9.3; SAS Institute, NC, USA).
Results
Cohort description
The total cohort (n = 53) included 67.9 % male and mean 
(±SD) age was 62.0 ±  9.3  years. Characteristics of par-
ticipants in the two groups are shown in Table 1. Age and 
sex distribution did not differ significant between the 
groups (p ≥ 0.58). However, the patients had higher body 
mass index compared to the controls (p < 0.001).
The cohort (n = 53) was similar to the total population 
in the main study (n = 90) in relation to age (p = 0.96), 
sex (p = 0.50), body mass index (p = 0.20) and smoking 
(p = 0.54).
The number of Th17 lymphocytes is reduced, while the TfH 
cells are increased in T2D patients
The total number of circulating whole blood cells is 
known to be increased in obese subjects [16]. Detailed 
analysis in T2D patients is yet to be carefully evaluated 
and linked to risk parameters. Hence, we determined if 
the number of T and B cells was modulated in our T2D 
patient cohort using the gating strategy shown in Addi-
tional file 1: Figure S1 and Fig. 1.
The frequency of viable cells in the peripheral blood 
was similar in healthy and T2D patients determined as 
frequency of 7AAD exclusion (data not shown). On a cel-
lular level, T2D patients was shown to have significantly 
(p = 0.008) lower total number of CD4+ T cells compared 
to healthy subjects (433 ± 24 and 579 ± 58 CD4+ T cells/
µl blood respectively) (Fig. 2a). In contrast, no difference 
between the T2D patients and healthy subjects was dis-
covered on CD8 T cell level (Fig. 2b). On a CD4 subset 
level, significant reduction of Th17 cells and a significant 
increase of TfH cells were observed (Fig. 2c, d). No dif-
ference between the T2D patients and healthy subjects 
was discovered on B cells level (Fig 2e). When adjusting 
for age, sex, body mass index and smoking the statistical 
difference between healthy and T2D patients on the CD4 
Table 1 Clinical characteristic of the participants
Data represent percentage (%) or mean ± SD. P values denote differences 
between controls and patients and were assessed by t test. Diabetes duration 
was non-normal distributed and is represented as mean [IQR]
Controls (n = 16) Patients (n = 37) P
Female, n (%) 6 (38) 11 (30) 0.58
Age (years) 61.4 ± 9.7 62.4 ± 9.4 0.74
Diabetes duration  
(years)
– 13.2 [8.0–23.0] –
Body mass index  
(kg/m2)
25.7 ± 3.0 31.7 ± 4.6 <0.001
HbA1c (mmol/mol) 36.5 ± 1.5 55.1 ± 11.9 <0.001
Smokers, n (%) 1 (6.3) 11 (30) 0.06
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level and the reduction of Th17 cells remained significant 
(p ≤ 0.003; Table 2).
Taken together, these results reveal that a reduction 
of the total number of CD4+ T cells and of Th17 cells 
is present in T2D, and that the reduction in this T2D 
cohort is independent of age, sex, body mass index and 
smoking.
Circulating M1‑like monocytes are reduced in T2D patients 
and lower CFR is associated with reduced expression 
of CD11chigh on monocytes
Low grade inflammation is characterized by an enhanced 
number of M1-like macrophages in adipose tissue and 
skeletal muscle. The total number of circulating mono-
cytes is not significantly modulated in patients at risk to 
Fig. 1 Circulating lymphocyte populations in diabetic patients and healthy controls. A representative gating strategy for T cell subsets is shown 
after first identifying the cells using gating strategy in Additional file 1: Figure S1. A total of 2 ml blood was analysed and the total number of each 
cell population was calculated as described in the “Methods” section
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develop T2D [17], while pre-clinical models of T2D have 
demonstrated that the monocyte population undergoes 
a repolarization from an initial M1-like phenotype into a 
M2-like phenotype in established disease [18]. To address 
if patients with established T2D display an altered profile 
of circulating monocyte polarization profile compared 
to healthy subjects associated with CFR, we performed 
analysis of peripheral blood in our T2D patient cohort. 
Using the gating strategy in Additional file  1: Figure S1 
and Fig. 3 monocyte subsets were identified.
Healthy subjects and T2D patients in our cohort both 
had approximately 300 monocytes/μl blood (Fig.  4a). 
Analysis of the monocyte compartment using the CD14 
and CD16 expression profile as functional markers of 
M1- and M2-like polarization [19, 20] uncovered a dis-
ease specific regulation of the polarization signature 
(Fig.  4b–d). The undifferentiated CD14+CD16− M0-like 
monocytes, show a moderate reduction in T2D blood 
compared to healthy subjects (257  ±  9 and 294  ±  20/
µl respectively), while the M2-like CD14+CD16+ cells 
show no difference between the groups (Fig.  4b, c). 
Most interestingly, the M1-like CD14dimCD16+ mono-
cytes, showed a strong and highly significant reduction 
(p < 0.001) in the T2D patients compared to the healthy 
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Fig. 2 Circulating lymphocyte populations in diabetic patients and healthy controls. The number of CD4 T cells (a), CD8 T cells (b), Th17 T cells (c), 
TfH T cells (d) and B cells (e) is shown. A total of 2 ml blood was analysed and the total number of each cell population was calculated as described 
in the “Methods” section. Each dot represents one individual and the horizontal line represents the mean value in each group. P values represent 
difference between groups assessed by t test
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subjects (30 ± 2 vs 44 ± 3/µl respectively) (Fig. 4d). No 
difference between groups was observed after adjusting 
for age, sex, body mass index, and smoking (p  ≥  0.16; 
Table  2). In contrast, a significant difference remained 
between healthy and T2D patients also after adjustment 
in the M1-like subset of monocytes (p = 0.006; Table 2). 
To further evaluate the reduction of M1-like monocytes, 
expression of the M1-associated cell marker CD11c on 
the monocyte subsets was performed. As expected, no 
modulation of CD11c expression on the M2- and M0-like 
monocyte subsets or on the total monocyte population 
was identified (Fig. 5a–c). In sharp contrast, the remain-
ing CD14dimCD16+ M1-like monocytes showed a highly 
significant increase of CD11c surface expression suggest-
ing that although the cell population as such is reduced 
the remaining cells have augmented capacity to respond 
in a pro-inflammatory manner (Fig. 5d). When perform-
ing adjustment for age, sex, body mass index and smok-
ing, this increase of CD11c surface expression remained 
significant (p = 0.031; Table 2).
In adjusted models, the CFR was higher with higher 
surface expression of CD11c both on total CD68+ mono-
cytes and on the M2-like CD14+CD16+ sub-population 
(p ≤ 0.038; Table 4).
Taken together, the results demonstrate that no sig-
nificant change is noted on the overall circulating mono-
cyte count in peripheral blood in T2D patients although 
a small reduction of M1-like monocytes is noted which 
show an enhanced M1-like polarization. However, most 
interestingly high expression of the M1-like marker 
CD11c was correlated to high CFR indicating that 
M1-like monocyte may be associated with improved car-
diac status in diabetic patients.
Circulating IL‑21R+ T cells and monocytes are reduced 
in T2D patients while high CFR is associated with high 
numbers of IL‑21R+ CD8 T cells
Cytokine receptor activation of leukocyte is essential 
and determines polarization and effector cell function. 
In obese subjects it has been demonstrated that IL-21 
Table 2 Circulating biomarkers in T2D patients vs. controls and in relation to Hba1c as continuous variable in adjusted 
analyses
Values represent the p values after adjustment for age, sex, body mass index, and smoking. Significant values are highlighted in italics
MFI mean fluorescence intensity
+ indicates higher values in patients and with increasing Hba1c; − indicates higher values in controls and with decreasing Hba1c
Variable Direction Controls (n = 16) vs. patients (n = 37) Hba1c (n = 53)
Circulating lymphocytes
 CD4Tcell_number − 0.003 0.09
 CD8tcell_number + 0.45 0.40
 B cells (number) CD19 #Events − 0.37 0.36
 Th17CCR6IL21R_number − 0.004 0.024
 TfH CXCR5+CCR6+ICOS+ (number) + 0.031 0.76
Circulating monocytes
 Mac_number (CD68) − 0.45 0.49
 M0 Mac number (CD14+CD16−) + 0.16 0.74
 M1 Mac number (C14dimCD16+) − 0.006 0.72
 M2 Mac number (CD14+CD16+) − 0.75 0.66
 Mac CD11c_MFI (CD68) − 0.93 0.24
 M0 CD14+CD16−CD11c) − 0.93 0.20
 M1 CD14dimCD16+CD11c) + 0.031 0.88
 M2 CD14+CD16+CD11c) − 0.65 0.92
IL-21R on leukocytes in peripheral blood
 CD4Tcell_IL21R_number − <0.0001 0.003
 CD8Tcell_IL21R_number − 0.0009 0.048
 B cell_IL21R_number − 0.14 0.18
 MacIL21R_number − 0.003 0.40
 CD4Tcell_IL21R_MFI − <0.0001 0.0001
 CD8Tcells_IL21R_MFI − 0.004 0.006
 B cell IL21R (MFI) − 0.023 0.076
 CD68 IL21R APC-A Mean − 0.38 0.62
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responsive cells are accumulated in adipose tissue where 
they are hypothesized to contribute to the metabolic dis-
ease progression by fuelling the inflammatory pathways 
[21]. To determine if a similar IL-21R modulation was 
present in T2D patients we evaluated the IL-21R surface 
expression levels (Fig. 6e) and the total number of IL21R+ 
cells and correlated that to the CFR.
The expression level of IL-21R on the circulating CD4+ 
T cells was highly significantly reduced (p  <  0.0001) 
compared to healthy controls (Fig.  6a, e). A similar, but 
less pronounced reduction of IL-21R expression level was 
demonstrated on CD8+ T cells and B cells (p =  0.0017 
and p =  0.0029 respectively) (Fig.  6b, c, e). In contrast, 
monocytes expressed low and non-modulated levels of 
IL-21R regardless disease (Fig.  6d, e). This reduced IL-
21R expression level resulted in a twofold reduction of 
the number of IL-21R CD4+ and CD8+ T cells in the T2D 
patients (Additional file  1: Figure S1A, B). Interestingly, 
Fig. 3 Total number of circulating monocyte populations in diabetic patients and healthy controls. Representative dot-plot and scatter-plots of 
CD14 vs CD16 and their expression of CD11c is shown after first identifying the cells using gating strategy in Additional file 1: Figure S1. A total of 
2 ml blood was analysed and the total number of each cell population was calculated as described in the “Methods” section
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no modulation was demonstrated on the number of IL-
21R positive B cells in T2D patients, whereas a moderate 
reduction of IL-21R monocytes was determined (Addi-
tional file 2: Figure S2C, D).
The reduction of IL-21R expression level and total 
number of IL-21R positive cells in the T2D cohort 
remained highly significant in the CD4+ and CD8+ sub-
sets also after adjustment for age, sex, body mass index 
and smoking (p ≤ 0.004; Table 2). In fact, the reduction 
of IL-21R level on CD4+ and CD8+ T cells and the num-
ber of CD4+-IL-21R positive cells was demonstrated to 
be a direct continuous variable for increased HbA1c 
(p ≤ 0.048; Table 2).
The CFR was higher in patients that had a high number 
of IL-21R expressing CD8+ T cells (p = 0.0024; Table 4). 
No association was noted on IL-21R+CD4 T cell or 
CD68+ monocyte level (Table 4).
Taken together, with increasing HbA1c a strong reduc-
tion of IL-21R+ T cells and IL-21R expression level was 
evident. Further the positive correlation between high 
CFR and elevated CD8+IL-21R T cells suggests that these 
IL-21R+ T cells may be associated with better cardiac 
function in diabetes.
The number of TLR4 lymphocytes is reduced in T2D 
patients, but inversely correlated with high CFR
TLR4 expression on B cells and T cells has been associ-
ated with immunosuppressive effect [22, 23]. Further, 
TLR4 expressing B cells are associated with increas-
ing body mass index and an inverse correlation exists 
between the number of TLR4 T cells and fasting plasma 
glucose in pre-diabetic as risk [24]. To determine if TLR4 
expression level is modulated in patients with T2D and 
associated with CFR, we performed flow cytometric 
analysis of the blood in our T2D cohort using the gating 
strategy from Additional file 1: Figure S1 and Fig. 7e.
The expression level of TLR4 on CD4+ and CD8+ T cell 
was not significantly modulated as a population (Fig. 7a, 
b). However, in both the CD4+ and in the CD8+ popula-
tion, six individuals showed highly elevated expression of 
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Fig. 4 Total number of circulating monocyte populations in diabetic patients and healthy controls. The number of CD68+ monocytes (a), M0-like 
CD14+CD16− monocytes (b), M2-like CD14+CD16+ monocytes (c) and M1-like CD14dimCD16+ monocytes (d) is shown. A total of 2 ml blood was 
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TLR4 compared to the remaining population in the T2D 
cohort which was not observed in the healthy subjects 
(Fig.  7a, b). No significant change in the TLR4 expres-
sion on B cells was demonstrated (Fig.  7c). However, 
the TLR4 expression level on monocytes in the blood 
was significantly increased in T2D patients compared to 
healthy subjects (Fig. 7d). In sharp contrast to the expres-
sion level of TLR4, the total number of circulating TLR4+ 
CD4+, CD8+ T cells and B cells was significantly reduced 
in the T2D cohort (Additional file 3: Figure S3A–C). The 
circulating monocytes expressing TLR4 was however not 
increased (Additional file 3: Figure S3D).
In fact, the reduced number of TLR4 CD4+ and CD8+ 
T cells remained even after adjustment for age, sex, body 
mass index and smoking (p ≤ 0.016; Table 3).
The CFR was higher with reduced surface expression of 
TLR4 on CD8+ T cells (p = 0.037; Table 4). There was no 
correlation between CFR and TLR4 expression on CD4+ 
T cells or on monocytes (Table 4).
Taken together, although individual subjects showed 
enhanced expression level of TLR4 on the T cells, the 
number of TLR4+ -T cells and B cells in the T2D cohort 
was significantly decreased. Further, the data demon-
strate that the reduced expression of TLR4 on T cells 
was correlated with enhanced CFR suggesting that TLR4 
lymphocytes may be related to cardiac functions in 
diabetes.
Attenuated presence of regulatory T cells in T2D patients 
and inverse association between Treg presence and CFR
Aberrant inflammation is present in several autoimmune 
diseases with enhanced activity in e.g. rheumatoid arthri-
tis as well as reduced activity in certain tumours [25]. 
Recently this was demonstrated to relate to a reduced 
presence and activity of regulatory lymphocytes in auto-
immune diseases and inversely an augmented activity of 
regulatory cells in tumours. To determine if regulatory T 
cells were modulated in our T2D cohort and associated 
with CFR, flow cytometric analysis of various Treg sub-
populations in the peripheral blood was performed using 
gating strategy from Figs. 1 and 8e.
The mean number of regulatory T cells (CD3+CD4
+CD25highCD127neg) phenotype was 52  ±  4 cells per 
µl blood in healthy controls (Fig.  8a). A highly signifi-
cant 26  ±  3  % reduction (p  <  0.001) of the number of 
CD25highCD127neg Tregs was present in the T2D patients 
(Fig.  8a). While on average 8.3 ±  0.9 cells/µl blood co-
expressed the regulatory transcription factor FoxP3 in 
healthy subjects, a significant (p = 0.016) 33 % reduction 
to 5.6 ±  0.4 cells/µl blood was evident in T2D patients 
Fig. 5 CD11c expression levels on monocyte subpopulations in diabetic patients and healthy controls. The CD11c expression on CD68+ mono-
cytes (a), M0-like CD14+CD16− monocytes (b), M2-like CD14+CD16+ monocytes (c) and M1-like CD14dimCD16+ monocytes (d) is shown. A total of 
2 ml blood was analysed and the total number of each cell population was calculated as described in the “Methods” section. Each dot represents 
one individual and the horizontal line represents the mean value in each group. P values represent difference between groups assessed by t test
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Fig. 6 IL-21R expression level on leukocyte populations in diabetic patients and healthy controls. The IL-21R expression on CD4+ T cells (a), CD8+ T 
cells (b), B cells (c) and CD68+ monocytes (d) is shown. Representative histogram analysis of IL-21R expression on CD19+, CD68+, CD4+ and CD8+ 
cells compared to the isotype antibody signal (e) that were first identified using the gating strategy from Figs. 1, 2 and Additional file 1: Figure S1. 
A total of 2 ml blood was analysed and the total number of each cell population was calculated as described in the “Methods” section. Each dot 
represents one individual and the horizontal line represents the mean value in each group. P values represent difference between groups assessed 
by t test
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(Fig.  8b). Further detailed analysis of the FoxP3+ cells 
revealed that 4.4 ± 0.4 cells/µl blood in healthy subjects 
also co-expressing CTLA4 while only 2.7  ±  0.3 cells/
µl (p  =  0.006; 38  % reduction) were CTLT4+ in T2D 
patients (Fig. 8c). To evaluate if the Tregs present in the 
blood had different transcriptional machinery associ-
ated with regulatory functions in healthy and diabetic 
subjects, the expression level of the transcription factor 
Fig. 7 TLR4 expression level on leukocyte populations in diabetic patients and healthy controls. The TLR4 expression on CD4+ T cells (a), CD8+ T 
cells (b), B cells (c) and CD68+ monocytes (d) is shown. Representative dot plot analysis of TLR4 expression on CD19, CD68, CD4 and CD8+ cells (e) 
that were first identified using the gating strategy from Figs. 1, 2 and Additional file 1: Figure S1. A total of 2 ml blood was analysed and the total 
number of each cell population was calculated as described in the “Methods” section. Each dot represents one individual and the horizontal line 
represents the mean value in each group. P values represent difference between groups assessed by t test
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FoxP3 was determined. The results clearly demonstrate 
that T cells in healthy subjects have a significantly higher 
expression level of FoxP3 than in T2D subjects in our 
cohort (Fig. 8d).
When adjusted for age, sex, body mass index and 
smoking the results remained significant (p  ≤  0.039; 
Table 3), except for the expression level of FoxP3 on the 
CD25+CD127− cells (p = 0.29; Table 3).
Intriguingly and in sharp contrast, in adjusted analyses, 
the CFR was higher with reduced number of regulatory 
T cells (p = 0.029; Table 4). This inverse correlation was 
even more pronounced with highly significantly lower 
expression of FoxP3 in the regulatory T cells in patients 
with high CFR (p = 0.001; Table 4).
Taken together, this demonstrates that the number of 
regulatory cells is highly significantly reduced in T2D 
patients and that the remaining T cells show an attenu-
ated differentiation towards a regulatory phenotype. 
Most importantly, high CFR was associated with low 
presence of regulatory T cells, suggesting that regulatory 
T cells might be linked to progression of cardiac compli-
cations in patients with T2D.
Discussion
In the present study we show that presence of diabetes 
is associated with a general T cell attenuation charac-
terized by reduced overall T cell, Th17, IL-21R+, Treg’s 
and TLR4+ T cell count, while the monocyte popula-
tion shows enhanced TLR4 expression. Further, our 
data revealed a reduced M1-like CD11c expression on 
our T2D cohort which was functionally associated with 
lower CFR. In contrast, we show for the first time in a 
T2D cohort increased TLR4 expression on CD8 T cells, 
increased Treg cell number and Treg maturation and 
reduced IL-21R expression on CD8 T cells to be function-
ally associated with impaired CFR. Even with early and 
multifactorial treatment, T2D patients show an enhanced 
incidence of cardiovascular complications. Presence of 
low grade systemic and local tissue inflammation is now a 
well-established characteristic and strong evidence exists 
linking vascular diabetic complications to inflammatory 
pathways [26]. However, to the best of our knowledge, 
we are the first to evaluate the relation between sys-
temic inflammatory signature and CFR in T2D patients. 
These findings might provide important novel informa-
tion potentially guiding future therapeutic approaches 
to reduce the burden of cardiovascular complications in 
T2D patients.
Signalling through the IL-21 receptor promotes prolif-
eration and contributes to effector mechanisms like viral 
elimination and antibody switch [27]. Interestingly, our 
T2D cohort demonstrated a significantly reduced expres-
sion level of IL-21R on circulating T cells compared to 
healthy subjects. Fabrizi et  al. recently demonstrated 
an increase of IL-21R mRNA transcripts in adipose tis-
sue in obese compared to healthy subjects [21]. Through 
local regulation of IRF4, these adipose immigrating 
IL-21R+ T cells performed immunoregulation which 
reduced the activity of Treg cells in the adipose tissue 
fuelling the low grade inflammation [21]. These IL-21R+ 
Table 3 Circulating biomarkers in T2D patients vs. controls and in relation to Hba1c as continuous variable in adjusted 
analyses
Values represent the p-values after adjustment for age, sex, body mass index, and smoking. Significant values are highlighted in italics
MFI Mean fluorescence intensity
+ indicates higher values in patients and with increasing Hba1c; − indicates higher values in controls and with decreasing Hba1c
Variable Direction Controls (n = 16) vs. patients (n = 37) Hba1c (n = 53)
TLR4 on leukocytes in peripheral blood
 CD4 T cell TLR4 (MFI) − 0.064 0.85
 CD8+ T cell TLR4 (MFI) − 0.17 0.87
 B cell TLR4 (MFI) − 0.023 0.076
 Mac TLR4 (MFI) + 0.017 0.58
 CD4cell_TLR4_number − <0.0001 0.006
 CD8Tcell__TLR4_number − 0.016 0.019
 BcellsTLR4_number − 0.0005 0.075
 MacTLR4_number + 0.23 0.90
Regulatory T cells and expression of FoxP3 in T cells
 Treg CD25+CD127− (number) − 0.002 0.016
 Treg CD25+CD127−FoxP3 (number) − 0.039 0.16
 Treg CD25+CD127−GITR+ (number) − 0.005 0.012
 TregCD25CD127FoxP3_MFI − 0.29 0.076
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T cells migrated to the obesity adipose tissue through 
specific chemokine patterns not identified in the study 
by Fabrizi et  al. [21]. A similar tissue homing of IL-21R 
T cells in diabetic patients has previously been shown 
to be dependent on the activity of CCR9 for gut-homing 
[28]. Due to both the gut-homing (CCR9 dependent) 
and adipose tissue homing (undefined) the net-result in 
the systemic compartment will be a reciprocal decrease 
of IL-21R+ circulating cells which is in accordance with 
and strengthen our novel observations. Furthermore, we 
recently demonstrated in a cohort of 20 subjects at risk to 
develop diabetes an inverse correlation of the frequency 
of IL-21R+ T cells with increased body mass index [17]. 
Thus, our novel findings in established T2D extend our 
previous observations in patients at risk of developing 
T2D that the systemic presence of IL-21R+ CD4 T cells 
is reduced in obesity, pre-diabetes and T2D. Based on the 
Fabrizi and the McGuire data this may be a direct con-
sequence of altered migratory patterns [21, 28]. Hence, 
circulating IL-21R+ T cells might act as a novel bio-
marker allowing identification of patients with metabolic 
syndromes.
Interestingly, on a CD4 subset level, a significant 
increase of TfH cells was observed in T2D patients with 
HbA1c. As these cells migrate through CXCR5, the accu-
mulation in the systemic compartment may indicate 
absence of or reduced levels of local chemokine produc-
tion of CXCL13. Interaction with CXCR5/CXCL13 is 
essential for the organization and establishment of lym-
phoid tissues [29]. In human visceral leishmaniasis infec-
tions reduce lymphoid tissue production of CXCL13 
results in impaired B/T cell interaction leading to sub-
optimal adoptive immunity [30]. Hence it is tempting 
to speculate that the reduced numbers of circulating 
T cells in our cohort may be associated with a similar 
mechanism.
Patients with a reduced number of systemic IL-21R+ 
CD8 T cells presented with a significantly lower CFR, 
indicative of impaired coronary microcirculation and 
hence a worse cardiovascular prognosis. This phenome-
non was not observed on CD4+ T cell level in the cohort. 
Discrepancies in tissue accumulation have previously 
been described in viral pre-clinical models and in human 
HIV patients [31, 32]. With the distinct expression pro-
file of IL-21R+ on CD4 and CD8 cells it is intriguing to 
speculate that IL-21R+ effector CD8 T cells rather than 
contributing to disease progression delivers yet to be 
identified signals protecting the vasculature in T2D. 
IL-21 and IL-21R inhibition has been frequently debated 
in the literature, where both higher and lower levels have 
been linked to atherosclerosis [33]. Our novel finding 
with impaired CFR in patients with a reduced number 
of circulating CD8-IL21R+ T cells add additional impor-
tant knowledge currently lacking in the understanding 
of the cardiovascular complications associated with T2D 
potentially aiding in the contradictory data around IL-21 
in vasculature complications. Consequently, low IL-21R 
on circulating CD8 T cells may be considered to be a 
good biomarker to identify patients with increased risk of 
having impaired CFR.
M1 macrophages have been linked to low-grade 
inflammation, insulin resistance and weight gain [34]. 
Tissue recruited monocytes differentiate into an M1 
Table 4 Circulating biomarkers in T2D patients in relation 
to coronary flow reserve in adjusted analyses
Values represent the p values after adjustment for age, sex, body mass index, 
smoking and diabetes duration. Significant values are highlighted in italics
MFI Mean fluorescence intensity
+ indicates higher values with increasing coronary flow reserve; − indicates 
lower values with increasing coronary flow reserve
Variable Direction Coronary flow 
reserve (n = 37)
Circulating monocytes
 Mac_number (CD68) + 0.23
 M0 Mac number (CD14+ CD16−) + 0.75
 M1 Mac number (C14dimCD16+) + 0.42
 M2 Mac number (CD14+CD16+) + 0.32
 Mac CD11c_MFI (CD68) + 0.038
 M0 CD14+CD16−CD11c) + 0.066
 M1 CD14dimCD16+CD11c) + 0.13
 M2 CD14+CD16+CD11c) + 0.037
IL-21R on leukocytes in peripheral blood
 CD4Tcell_IL21R_number + 0.23
 CD8Tcell_IL21R_number + 0.002
 B cell_IL21R_number + 0.72
 MacIL21R_number − 0.59
 CD4Tcell_IL21R_MFI + 0.093
 CD8Tcells_IL21R_MFI + 0.41
 B cell IL21R (MFI) + 0.83
 CD68 IL21R APC-A mean − 0.68
TLR4 on leukocytes in peripheral blood
 CD4 T cell TLR4 (MFI) + 0.17
 CD8+ T cell TLR4 (MFI) − 0.037
 B cell TLR4 (MFI) − 0.60
 Mac TLR4 (MFI) + 0.75
 CD4cell_TLR4_number + 0.97
 CD8Tcell__TLR4_number − 0.32
 BcellsTLR4_number + 0.22
 MacTLR4_number + 0.36
Regulatory T cells and expression of FoxP3 in T cells
 Treg CD25+CD127− (number) − 0.88
 Treg CD25+CD127−FoxP3 (number) − 0.029
 Treg CD25+CD127−GITR + (number) − 0.31
 TregCD25CD127FoxP3_MFI − 0.001
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macrophage phenotype and their accumulation leads to 
an imbalance between M1 and M2 macrophages locally 
in the tissue [34]. Increased pro-inflammatory cytokine 
production from M1 macrophages and/or reduced 
anti-inflammatory signals from the M2 macrophages 
promote adipose tissue dysfunction and impairs glu-
cose tolerance in the early stages of diabetes [1]. In con-
trast, in late-stage established diabetes the macrophages 
Fig. 8 Circulating regulatory populations in diabetic patients and healthy controls. The number of Tregs (CD4+CD25+CD127−) T cells (a), FoxP3high 
Tregs (CD4+CD25+ CD127−) T cells (b), CTLA4high Tregs (CD4+CD25+ CD127−FoxP3high) T cells (c) and FoxP3 MFI on Tregs (CD4+CD25+ CD127−) T 
cells (d). Representative dot plot analysis of Treg sub-populations (CD3+CD4+CD25+CD127−; CD3+CD4+CD25+CD127−FoxP3+; CD3+CD4+CD25+C
D127−FoxP3+CTLA4+) (e) that were first identified using the gating strategy from Figs. 1, 2 and Additional file 1: Figure S1. A total of 2 ml blood was 
analysed and the total number of each cell population was calculated as described in the “Methods” section. Each dot represents one individual and 
the horizontal line represents the mean value in each group. P values represent difference between groups assessed by t test. MFI mean fluores-
cence intensity
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exhibit a polarization profile closely associated with 
remodelling M2-like macrophages in mice [18, 20]. This 
disease-dependent maturation and polarization of the 
inflammatory response may directly contribute to the 
excessive tissue fibrosis which is the hallmark of dia-
betic complications [18, 35]. Herein we now extend our 
previous pre-clinical observations and demonstrate 
that macrophages associated with pro-inflammation 
(M1-like) are significantly reduced in circulation also in 
clinical samples from T2D patients. The pro-inflamma-
tory M1-like cells may have accumulated in adipose and 
skeletal muscle contributing to the insulin resistance 
resulting in a reciprocal loss in the systemic compart-
ment [36]. The observation that the remaining periph-
eral monocytes in patients with reduced CFR show lower 
expression of CD11c, i.e. classical M1-like monocytes, 
is intriguing. These cells are associated with production 
of pro-inflammatory cytokines but not with repair and 
remodelling mechanisms [37]. Further, CD11c on mono-
cytes has been shown essential for monocyte adherence 
and migration into atherosclerotic plaques in pre-clinical 
models [38]. The discrepancies between the pre-clinical 
macrovascular diseases and the clinical microvascular 
disorder could be due to analyses in different disease seg-
ments and at different locations. With our demonstra-
tion that the overall M1-like monocytes are reduced in 
number, but the remaining monocytes express elevated 
CD11c indicates that low CD11c expression could be 
used as a functional biomarker to identify patients with 
impaired CFR.
Regulatory T cells control adaptive immune responses 
by suppressing T cells, NK cells, NKT cells, B cells and 
dendritic cells [39]. Regulatory T cells and subsets of 
CD4+ Th2 cells are known to secrete anti-inflammatory 
and homeostatic cytokines with the ability to inhibit and 
modulate macrophage recruitment and activation state 
[40]. Previous studies have shown that in obese adipose 
tissue, the regulatory T cells were diminished leaving 
these patients at risk to progress into diabetes [41]. In line 
with this, we demonstrate that the number of circulating 
regulatory cells is reduced in patients with T2D com-
pared to healthy controls. Further, the remaining T cells 
showed an attenuated differentiation towards a regula-
tory phenotype. Similar reductions have been described 
in other chronic diseases often associated with immune 
deficiency (e.g. HIV) where it is strongly associated with 
a poor prognosis and active progression of disease devel-
opment [42].
Transforming growth factor beta (TGF-β) is a crucial 
pleiotropic cytokine associated with the development of 
Tregs and Th17 cells [43]. In our cohort of patients with 
T2D, we showed a reduction of both Tregs and Th17. 
This suggests that neither the pro-inflammatory Th17 
nor the regulatory Tregs may be suitable functional bio-
markers of T2D as they are both down-regulated in the 
same disease stage. In sharp contrast, they may be good 
disease and functional biomarkers for coronary diabetic 
complications as they both are strongly associated with 
impaired coronary microcirculation. Most interest-
ingly, enhanced numbers of Tregs as well as the elevated 
expression level of FoxP3 on the regulatory T cells was 
associated with impaired coronary microcirculation in 
our cohort. TGF-β promotes tissue remodelling and is 
highly associated with the development of Tregs [44]. 
In healthy subjects this is in balance; accordingly, injury 
induces a pro-inflammatory response which after a short 
period is turned down by locally produced TGF-β that 
promotes Tregs leading to repair [44]. In contrast, in 
patients with chronic disease excessive TGF-β is pro-
duced in the “termination phase”. This leads to polariza-
tion towards M2-like macrophages, tissue remodelling, 
stiffening of tissues and in the end of this cascade to 
atherosclerosis [45]. In our T2D cohort, patients with 
increased Tregs had a lower CFR, indicative of impaired 
coronary microcirculation. Our data might suggest that 
augmented down-regulation is associated with exces-
sive locally produced TGF-β leading to stiffening of the 
tissue. Hence, the balance is disturbed which may favour 
remodelling rather than normal tissue repair.
Along the same line, TLR4 expression on CD8 T cells 
was lower in patients with reduced CFR. This is highly 
interesting as TLR4 expressing lymphocytes has been 
described as regulators of the immune responses by pro-
viding signals that terminate pro-inflammation, while 
TLR4 expressing macrophages classically is known as 
potentiators of pro-inflammation [46]. The detrimental 
role of TLR4 in atherosclerosis through monocytes and 
macrophages is well established [47]. Our novel finding 
that reduced TLR4 on CD8 lymphocytes correlates to 
an impaired coronary microcirculation in T2D patients 
is a novel and potentially important finding placing 
immune-modulating CD8 T cells in a novel tissue pro-
tecting role. Thus, caution should be taken when con-
sidering therapies inhibiting TLR4 in vascular diabetic 
complications as this might risk to further worsen the 
coronary microcirculation by inhibiting the TLR4+CD8 
T cells.
Matrougui et  al. [48] elegantly showed that injections 
with Tregs in hypotensive mice lead to reduced mac-
rophage activation and infiltration, lower TNFa levels 
and improved coronary arteriolar endothelium-depend-
ent relaxation. Hence while Tregs may play a protective 
role in the development of coronary arteriolar endothe-
lial dysfunction in hypertension, our data suggest that 
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in chronic diabetic induced disease increased Tregs may 
actually correlate to impaired coronary microcirculation.
Recent findings also depict the role of inflammation 
and immune dysregulation on coronary microvascular 
function. A study, including patients with non-obstruc-
tive coronary artery disease, demonstrated an inde-
pendent relationship between higher levels of soluble 
urokinase-type plasminogen activator receptor (suPAR), 
a surrogate of systemic inflammation and immune func-
tion, and lower CFR [49].
Multiple factors can be involved in impairment of CFR 
including hyperglycemia, insulin resistance, endothelial 
dysfunction and increased cardiac sympathetic activ-
ity [50]. Moreover, recent cross sectional studies have 
shown lower CFR to be associated with decreased aortic 
distensibility [51] and left ventricular diastolic dysfunc-
tion [52] in asymptomatic patients with type 2 diabetes. 
Treatment of diabetic hyperglycemia may improve CFR 
[50]. However, in a short-term (10  weeks) study, the 
GLP-1 analogue liraglutide did not have any significant 
effect on CFR (assessed by Doppler flow echocardiogra-
phy) in patients with type 2 diabetes [53]. These conflict-
ing results might be explained by short observation times 
and selection criteria.
Strengths and limitations
A major strength of this study is the use and combination 
of two advanced procedures; FACS analyses and assess-
ment of CFR by cardiac Rb82 PET/CT (a sensitive marker 
of coronary microcirculation (currently considered the 
gold standard) [50] in a clinical relevant setting including 
both T2D patients and healthy controls. Despite these 
strengths, limitations merit considerations. As the aim 
of this study was hypothesis generating and thought pro-
voking, we investigated a long series of markers. Further, 
due to the demanding procedures applied, the number of 
included participants is relatively low leading to limited 
power.
Conclusions
Herein we describe for the first time novel insights link-
ing inflammatory signatures to the CFR. A pattern 
emerged suggesting low presence of Tregs, FoxP3 expres-
sion and TLR4+CD8 T cells together with enhanced of 
IL21R+ CD8 T cells and CD11c M1-like monocytes in 
peripheral blood to be associated with high CFR. Our 
data imply that low CFR seems to be associated with an 
attenuated inflammatory signature in combination with 
elevated regulatory activity. Our data provide important 
clues about inflammation-diabetes-CFR that may be use-
ful when designing novel therapeutic agents filling the 
current unmet medical need as well as providing novel 
non-invasive functional biomarkers useful to identify 
patients at risk to develop severe T2D complications.
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leukocytes.
Additional file 2: Figure S2. Total number of IL-21R+ leukocyte popula-
tions in diabetic patients and healthy controls. The number of IL-21R+ 
CD4+ T cells (A), CD8+ T cells (B), B cells (C) and CD68+ monocytes (D) is 
shown. A total of 2 ml blood was analysed and the total number of each 
cell population was calculated as described in the Materials and Methods 
section. Each dot represents one individual and the horizontal line 
represents the mean value in each group. P values represent difference 
between groups assessed by t test.
Additional file 3: Figure S3. Total number of TLR4+ leukocyte popula-
tions in diabetic patients and healthy controls. The number of TLR4+ CD4+ 
T cells (A), CD8+ T cells (B), B cells (C) and CD68+ monocytes (D) is shown. 
A total of 2 ml blood was analysed and the total number of each cell 
population was calculated as described in the Materials and Methods sec-
tion. Each dot represents one individual and the horizontal line represents 
the mean value in each group. P values represent difference between 
groups assessed by t test.
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